{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVA", "query": { "intervention": "IVA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 208, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:38:49.031Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT03911713", "title": "A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-561", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2019-04-17", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2022-01-25", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911713" }, { "nct_id": "NCT02398240", "title": "Brentuximab for Newly Diagnosed Hodgkin Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mitchell Cairo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "29 Years", "sex": "ALL", "summary": "1 Year to 29 Years" }, "enrollment_count": 40, "start_date": "2015-05", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02398240" }, { "nct_id": "NCT02166463", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ann Arbor Stage IIB Hodgkin Lymphoma", "Ann Arbor Stage IIIB Hodgkin Lymphoma", "Ann Arbor Stage IVA Hodgkin Lymphoma", "Ann Arbor Stage IVB Hodgkin Lymphoma", "Childhood Hodgkin Lymphoma", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Bleomycin Sulfate", "type": "BIOLOGICAL" }, { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "2 Years to 22 Years" }, "enrollment_count": 600, "start_date": "2015-03-19", "completion_date": "2026-10-03", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 182, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02166463" }, { "nct_id": "NCT03634267", "title": "MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Papillomavirus-Related Carcinoma", "Human Papillomavirus-Related Cervical Carcinoma", "Stage IB2 Cervical Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Vaginal Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Vaginal Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Vaginal Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8" ], "interventions": [ { "name": "Internal Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 26, "start_date": "2018-08-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03634267" }, { "nct_id": "NCT00091286", "title": "Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 11, "start_date": "2003-03-24", "completion_date": "2008-02-15", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091286" }, { "nct_id": "NCT00085631", "title": "Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "hyperthermia treatment", "type": "PROCEDURE" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "external beam radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Mark Dewhirst", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 101, "start_date": "2003-03", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085631" }, { "nct_id": "NCT01931839", "title": "A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation" ], "interventions": [ { "name": "Lumacaftor Plus Ivacaftor Combination", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1164, "start_date": "2013-10", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-05-12", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931839" }, { "nct_id": "NCT01609062", "title": "Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mucopolysaccharidosis IVA", "Morquio A Syndrome", "MPS IVA" ], "interventions": [ { "name": "BMN 110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 25, "start_date": "2012-04", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-02-01", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 4, "location_summary": "Oakland, California • Chicago, Illinois • New York, New York + 1 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609062" }, { "nct_id": "NCT01225211", "title": "Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Lumacaftor", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Lumacaftor Placebo", "type": "DRUG" }, { "name": "Ivacaftor Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2010-10", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-10-05", "last_synced_at": "2026-09-02T21:38:49.031Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225211" } ] }